cofetuzumab pelidotin

Drug Overview

Cofetuzumab pelidotin is a highly specialized, investigational cancer medication. It belongs to an advanced class of treatments known as Targeted Therapies or “Smart Drugs.” Unlike traditional chemotherapy that attacks both healthy and cancerous cells, this medication is designed to seek out and destroy only specific cancer cells.

This precision helps to deliver strong cancer-fighting medicine exactly where it is needed while attempting to spare the rest of the body. Currently, cofetuzumab pelidotin is being studied in clinical trials for patients with certain advanced cancers that have not responded to other treatments.

• Generic Name: Cofetuzumab pelidotin (also known in research as PF-06647020 or ABBV-647).
• US Brand Names: None yet. It is an investigational drug and is not yet sold under a commercial brand name.
• Drug Class: Antibody-Drug Conjugate (ADC) / Targeted Therapy.
• Route of Administration: Intravenous (IV) injection.
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it is actively being evaluated in clinical trials.
  
  Get details on cofetuzumab pelidotin and its oncology applications. Trust our expert medical team for advanced clinical care tailored to you.

What Is It and How Does It Work? (Mechanism of Action)

To understand how cofetuzumab pelidotin works, it helps to think of it as a microscopic guided missile. As an Antibody-Drug Conjugate (ADC), it is made of three key parts: a targeting system (the antibody), a chemical bridge (the linker), and a cancer-killing payload (a drug called auristatin-0101).

Here is how this “Smart Drug” works at the molecular level:

1. Finding the Target: The antibody part of the drug is designed to look for a specific protein called Protein Tyrosine Kinase 7 (PTK7). PTK7 is found in abnormally high amounts on the surface of many tumor cells, especially in lung, breast, and ovarian cancers.
2. Entering the Cell: Once the drug finds and attaches to the PTK7 receptor on the outside of the cancer cell, the cell absorbs the drug, pulling it inside.
3. Releasing the Payload: Inside the cancer cell, natural enzymes break the chemical “linker” bridge. This releases the powerful cancer-killing drug (auristatin-0101) directly inside the tumor cell.
4. Stopping Cell Growth: The released payload specifically attacks the cell’s internal skeleton (microtubules). It blocks them from building properly. Without this internal structure, the cancer cell cannot divide and grow (a stage called G2/M phase arrest), which ultimately forces the cancer cell to die (apoptosis).

FDA Approved Clinical Indications

Because cofetuzumab pelidotin is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively studied in approved clinical trials for the following areas:

• Oncological Uses (In Clinical Trials):
  • Non-Small Cell Lung Cancer (NSCLC): Used in patients with recurrent lung cancer that expresses the PTK7 protein and has not responded to previous therapies.
  • Triple-Negative Breast Cancer (TNBC): Evaluated for advanced or metastatic breast cancer, sometimes in combination with other experimental drugs.
  • Ovarian Cancer: Studied in patients with platinum-resistant ovarian tumors.
• Non-oncological Uses:
  • None. This drug is currently only being studied for cancer treatment.

Dosage and Administration Protocols

Because cofetuzumab pelidotin is still in clinical trials, doses can vary based on the specific study protocol. The table below outlines the standard guidelines observed in recent Phase 1 and Phase 2 trials.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) have provided early but promising data regarding how well cofetuzumab pelidotin works:

• Non-Small Cell Lung Cancer (NSCLC): In recent Phase 1b trials, patients with recurrent lung cancer showed an Overall Response Rate (ORR) of roughly 18%. In a subgroup of patients whose tumors had very high levels of the PTK7 protein, the treatment was even more effective, leading to tumor shrinkage in about 30% of those cases.
• Triple-Negative Breast Cancer (TNBC): In studies combining cofetuzumab pelidotin with other targeted therapies (like gedatolisib), researchers noted an Overall Response Rate between 16.7% and 18.8%. The clinical benefit rate (which includes patients whose tumors stopped growing for a long time) was around 28% to 31%. The median time before the disease progressed (Progression-Free Survival) was roughly 2.0 months in these heavily pre-treated patients.

Safety Profile and Side Effects

Like all cancer treatments, cofetuzumab pelidotin can cause side effects. Because it delivers the toxin directly to cancer cells, it aims to reduce widespread damage, but some healthy cells can still be affected.

Black Box Warning

There is currently no FDA Black Box Warning for cofetuzumab pelidotin because it is an investigational agent.

Common Side Effects (>10%)

• Nausea and Vomiting: Feeling sick to your stomach.
• Fatigue: Feeling unusually tired or weak.
• Alopecia: Partial or complete hair loss.
• Headache: Mild to moderate head pain.
• Mucositis: Soreness, redness, or ulcers inside the mouth.
• Anorexia: Loss of appetite.

Serious Adverse Events

• Severe Neutropenia: A major drop in white blood cells, which are essential for fighting off infections. In studies, about 25% of patients experienced Grade 3 or higher neutropenia, which requires strict medical attention.
• Dose-Limiting Toxicities: In a small number of patients at higher doses, severe headaches and extreme fatigue forced doctors to lower the dose or pause treatment.

Management Strategies

• For Nausea: The medical team will usually provide anti-nausea medications before the infusion.
• For Neutropenia: Patients will have regular blood tests (CBCs). If white blood cell counts drop too low, doctors may delay the next dose or provide medications that help the body make new white blood cells.

Connection to Stem Cell and Regenerative Medicine

Cofetuzumab pelidotin has a strong connection to cancer stem cell research. The target of this drug, the PTK7 protein, is not just found on standard cancer cells; it is highly enriched in “tumor-initiating cells,” which are often called cancer stem cells. These mutant stem cells are notorious for resisting traditional chemotherapy and are often the root cause of cancer relapse. By targeting the PTK7 receptor, this Targeted Therapy aims to eliminate these cancer stem cells at their source, potentially preventing the tumor from growing back and offering a new pathway for long-term disease control.

Patient Management and Practical Recommendations

To ensure safety and the best possible outcome during a clinical trial, patients must follow specific guidelines before, during, and after receiving cofetuzumab pelidotin.

Pre-treatment Tests to be Performed

• Biomarker Testing: A biopsy sample of the tumor must be tested in a lab to ensure it has high levels of the PTK7 protein. If the tumor does not have this protein, the drug will not work.
• Complete Blood Count (CBC): To ensure white blood cells, red blood cells, and platelets are at safe levels before starting.
• Pregnancy Test: A negative pregnancy test is strictly required for women of childbearing age, as the drug’s payload can severely harm an unborn baby.
• Baseline Scans: Standard CT or MRI scans are done to measure the exact size of the tumors before treatment starts.

Precautions During Treatment

• Patients will be monitored closely by nursing staff during the IV infusion for any signs of an allergic reaction.
• Because of the risk of neutropenia, patients must be highly cautious about catching infections.

“Do’s and Don’ts” List

• DO attend all scheduled blood test appointments. Monitoring your white blood cell count is critical for your safety.
• DO report any fever, chills, or signs of infection to your doctor immediately. A fever during treatment is a medical emergency.
• DO drink plenty of fluids and eat small, frequent meals if you experience nausea or loss of appetite.
• DON’T ignore severe headaches or extreme exhaustion. Let your care team know so they can adjust your care plan.
• DON’T receive any live vaccines while undergoing this therapy, as your immune system may be temporarily weakened.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Cofetuzumab pelidotin is an investigational drug and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, side effects, and eligibility for clinical trials.